Posts

2021: A Year in Review for the Psychedelics Business

Our resident Psychedelic Investor looks back at some of this growing industry's biggest moments and how they may shape the business in 2022.
Psychedelic Business News Spotlight - December 24

Psychedelic Business Spotlight – December 24

This week in psychedelic business news: FDA green lights a new psilocybin study; MindMed commences LSD treatment for ADHD; Sage Institute shuffles leadership.
Psychedelic Business Spotlight – December 17

Psychedelic Business Spotlight – December 17

This week in psychedelic business news: Cybin steps closer to a new patent; MindMed appoints new CEO; MAPS and Wesana Health resume negotiations.

Compass Pathways Study Finds SSRI Drugs Did Not Impede Psilocybin’s Therapeutic Effect

Chief Medical Officer Guy Goodwin calls study "a strong signal that COMP360 psilocybin therapy could be an adjunctive treatment to SSRI antidepressant as well as a monotherapy."
New Study Suggests SSRI Drugs Can Be Used Safely with Psilocybin to Treat DepressionShutterstock.com

New Study Suggests SSRI Drugs Can Be Used Safely with Psilocybin to Treat Depression

“If the results are confirmed in subsequent studies ... antidepressants may no longer need to be stopped for psilocybin treatment,” says MindMed Executive President Dr. Miri Halperin Wernli.

Psychedelic Business Spotlight: November 19

This week in psychedelic business news: Companies partner on new dosage method; MindMed investigates LSD microdosing; Health Canada allows a psilocybin production campus.

Psychedelic Business Spotlight: October 29

This week in psychedelic business news: MindMed's MDMA research pipeline to treat Autism Spectrum Disorder; Cybin EMBARKs; Awakn and MindCure partner to heal alcoholism.
Why Psychedelic Stocks Have Crashed in the Last 3 Months

Why Psychedelic Stocks Have Crashed in the Last 3 Months

Our resident psychedelic investor explains why psychedelic stocks are plummeting, and why patience can pay off big time.
MindMed, Forian Developing Personalized Psychiatry for Anxiety Disorders

MindMed, Forian Developing Personalized Psychiatry for Anxiety Disorders

MindMed is currently conducting several clinical trials using psychedelic-inspired medicines, including studying LSD experiential therapy for anxiety, LSD microdosing for adult ADHD, and 18-MC for opioid withdrawal.
Psychedelic Spotlight Business Round Up July 30

Psychedelic Business Spotlight: July 30, 2021

This week in psychedelic business news: More psychedelic-assisted therapy clinics, recruitment begins in early DMT trial, and Filament gets more Health Canada love.